Home › Research › Drug development
Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies
Shubham Sharma, Phani Veeranki, Dr Anuj Mubayi, Santosh Nambari. Open Science Framework, 2026-08-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neurodegenerative disorders (NDDs), primarily alzheimer, dementia, parkinson, and rare NDD disease, present an escalating global health crisis, currently affecting over 55 million older adults worldwide. Current therapeutic options are largely limited to temporary symptomatic relief, fundamentally failing to modify underlying disease progression. Consequently, drug repurposing has emerged as a crucial strategy, with Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, semaglutide; gaining significant attention. Despite the growing body of RWE evaluating the real-world safety and effectiveness of these drugs in NDDs, there is a distinct lack of comprehensive scoping reviews to encapsulate, categorize, and synthesize these scattered observational findings. To address this gap, we are conducting a scoping review to systematically map the available real-world evidence of GLP-1 RAs for neurodegenerative disorders, outlining current clinical insights and directing future trial designs.
What this study adds
Evidence grade: Low
This is a plan for a scoping review that will map existing observational studies of GLP-1 receptor agonists in neurodegenerative disorders. It reports no new results and therefore cannot say whether these drugs treat or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sharma, S., Veeranki, P., Mubayi, D. A., & Nambari, S. (2026). Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies. Open Science Framework. https://doi.org/10.17605/osf.io/ng7mu
Vancouver
Sharma S, Veeranki P, Mubayi DA, Nambari S. Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies. Open Science Framework. 2026. doi:10.17605/osf.io/ng7mu.
BibTeX
@article{sharma2026-0b097590,
author = {Sharma, Shubham and Veeranki, Phani and Mubayi, Dr Anuj and Nambari, Santosh},
title = {{Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies}},
journal = {Open Science Framework},
year = {2026},
doi = {10.17605/osf.io/ng7mu},
url = {https://doi.org/10.17605/osf.io/ng7mu}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Consequently, drug repurposing has emerged as a crucial strategy, with Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, semaglutide; gaining significant attention.
Why it matters
This is a plan for a scoping review that will map existing observational studies of GLP-1 receptor agonists in neurodegenerative disorders. It reports no new results and therefore cannot say whether these drugs treat or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, impact for its field and year, senior author's track record and institution's track record, so those were left out: it earned 26 of the 83 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Open Science Framework) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Santosh Nambari holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 83 | Scored on 16 of 20 parts. We have no data for the rest, so they are left out: 26 of the 83 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.